A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
Year: 2017
Type: article
Abstract: The interaction of acute myeloid leukemia (AML) blasts with the bone marrow (BM) microenvironment provides potent protection against both spontaneous apoptosis and chemotherapy. 1 Similar to normal hematopoietic stem cells (HSCs), AML blasts express many of the same adhesion molecules such as CXCR4, VLA-4, VLA-5 and CD44, which allow them to interact with the marrow microenvironment. We and others have demonstrated in murine models that CXCR4 inhibitors can mobilize AML cells from the BM into the peripheral blood and enhance the anti-leukemic effects of chemotherapy. 2 , 3 We have also demonstrated in a previous phase 1/2 study that plerixafor, a small molecule inhibitor of CXCR4, can be safely combined with chemotherapy in patients with relapsed or refractory AML with encouraging response rates. 4
Source: Blood Cancer Journal
DOI: 10.1038/bcj.2017.21
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,290
Awards: G1114310655, OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE, G2029646967, G299873027, TARGETING THE CXCR4-SDF1 AXIS AS THERAPY FOR RELAPSED/REFRACTORY AML, G4649233572, G5449461467, TARGETING AML-STROMAL INTERACTIONS, G7702384033, G8242737674, Targeting Leukemia Stromal Interactions in AML, G8914033231, G9000319192, BM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIES, Cancer Center Support Grant
OpenAlex ID: W2592358054